GFR tyrosine kinases inhibitors in cancer treatment: In vitro and in vivo evidence

Anna Elisa Quatrale, Letizia Porcelli, Nicola Silvestris, Giuseppe Colucci, Angelo Paradiso, Amalia Azzariti

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

The increasing understanding of the molecular mechanisms of neoplastic transformation and progression has prompted the search for novel drugs that could interfere with the intracellular targets involved in this process. EGFR is implicated in the development and progression of the majority of the common human epithelial cancer; therefore different agents have been developed to block EGFR activation in cancer cells. This review focuses on EGFR-tyrosine kinase inhibitors in clinical practice that interfere with ATP binding, inhibiting tyrosine kinase activity and subsequently blocking signal transduction from EGFR. We report current knowledge on molecular mechanisms underlying the anticancer activity of EGFR-tyrosine kinase inhibitors in preclinical models, with particular attention to EGFR downstream effectors responsible for treatment efficacy or resistance.

Original languageEnglish
Pages (from-to)1962-1972
Number of pages11
JournalFrontiers in Bioscience
Volume16
Issue number5
DOIs
Publication statusPublished - Jan 1 2011

Fingerprint

Oncology
Protein-Tyrosine Kinases
Neoplasms
Signal transduction
Signal Transduction
Adenosine Triphosphate
Chemical activation
Cells
Pharmaceutical Preparations
In Vitro Techniques

Keywords

  • Biological activity
  • Cancer treatment
  • EGFR tyrosine kinase inhibitors
  • Erlotinib
  • Gefitinib
  • Lapatinib
  • Mechanisms of action
  • Review

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Medicine(all)

Cite this

GFR tyrosine kinases inhibitors in cancer treatment : In vitro and in vivo evidence. / Quatrale, Anna Elisa; Porcelli, Letizia; Silvestris, Nicola; Colucci, Giuseppe; Paradiso, Angelo; Azzariti, Amalia.

In: Frontiers in Bioscience, Vol. 16, No. 5, 01.01.2011, p. 1962-1972.

Research output: Contribution to journalArticle

Quatrale, Anna Elisa ; Porcelli, Letizia ; Silvestris, Nicola ; Colucci, Giuseppe ; Paradiso, Angelo ; Azzariti, Amalia. / GFR tyrosine kinases inhibitors in cancer treatment : In vitro and in vivo evidence. In: Frontiers in Bioscience. 2011 ; Vol. 16, No. 5. pp. 1962-1972.
@article{5b2ff5ae9a0d403db6399deae95f8e7d,
title = "GFR tyrosine kinases inhibitors in cancer treatment: In vitro and in vivo evidence",
abstract = "The increasing understanding of the molecular mechanisms of neoplastic transformation and progression has prompted the search for novel drugs that could interfere with the intracellular targets involved in this process. EGFR is implicated in the development and progression of the majority of the common human epithelial cancer; therefore different agents have been developed to block EGFR activation in cancer cells. This review focuses on EGFR-tyrosine kinase inhibitors in clinical practice that interfere with ATP binding, inhibiting tyrosine kinase activity and subsequently blocking signal transduction from EGFR. We report current knowledge on molecular mechanisms underlying the anticancer activity of EGFR-tyrosine kinase inhibitors in preclinical models, with particular attention to EGFR downstream effectors responsible for treatment efficacy or resistance.",
keywords = "Biological activity, Cancer treatment, EGFR tyrosine kinase inhibitors, Erlotinib, Gefitinib, Lapatinib, Mechanisms of action, Review",
author = "Quatrale, {Anna Elisa} and Letizia Porcelli and Nicola Silvestris and Giuseppe Colucci and Angelo Paradiso and Amalia Azzariti",
year = "2011",
month = "1",
day = "1",
doi = "10.2741/3833",
language = "English",
volume = "16",
pages = "1962--1972",
journal = "Frontiers in Bioscience - Landmark",
issn = "1093-9946",
publisher = "Frontiers in Bioscience",
number = "5",

}

TY - JOUR

T1 - GFR tyrosine kinases inhibitors in cancer treatment

T2 - In vitro and in vivo evidence

AU - Quatrale, Anna Elisa

AU - Porcelli, Letizia

AU - Silvestris, Nicola

AU - Colucci, Giuseppe

AU - Paradiso, Angelo

AU - Azzariti, Amalia

PY - 2011/1/1

Y1 - 2011/1/1

N2 - The increasing understanding of the molecular mechanisms of neoplastic transformation and progression has prompted the search for novel drugs that could interfere with the intracellular targets involved in this process. EGFR is implicated in the development and progression of the majority of the common human epithelial cancer; therefore different agents have been developed to block EGFR activation in cancer cells. This review focuses on EGFR-tyrosine kinase inhibitors in clinical practice that interfere with ATP binding, inhibiting tyrosine kinase activity and subsequently blocking signal transduction from EGFR. We report current knowledge on molecular mechanisms underlying the anticancer activity of EGFR-tyrosine kinase inhibitors in preclinical models, with particular attention to EGFR downstream effectors responsible for treatment efficacy or resistance.

AB - The increasing understanding of the molecular mechanisms of neoplastic transformation and progression has prompted the search for novel drugs that could interfere with the intracellular targets involved in this process. EGFR is implicated in the development and progression of the majority of the common human epithelial cancer; therefore different agents have been developed to block EGFR activation in cancer cells. This review focuses on EGFR-tyrosine kinase inhibitors in clinical practice that interfere with ATP binding, inhibiting tyrosine kinase activity and subsequently blocking signal transduction from EGFR. We report current knowledge on molecular mechanisms underlying the anticancer activity of EGFR-tyrosine kinase inhibitors in preclinical models, with particular attention to EGFR downstream effectors responsible for treatment efficacy or resistance.

KW - Biological activity

KW - Cancer treatment

KW - EGFR tyrosine kinase inhibitors

KW - Erlotinib

KW - Gefitinib

KW - Lapatinib

KW - Mechanisms of action

KW - Review

UR - http://www.scopus.com/inward/record.url?scp=79954988228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954988228&partnerID=8YFLogxK

U2 - 10.2741/3833

DO - 10.2741/3833

M3 - Article

C2 - 21196276

AN - SCOPUS:79954988228

VL - 16

SP - 1962

EP - 1972

JO - Frontiers in Bioscience - Landmark

JF - Frontiers in Bioscience - Landmark

SN - 1093-9946

IS - 5

ER -